

OCTOBER 2025

Date	Headline and Source	Link	Summary
1 st October	Weight-loss drug Ozempic receives CDSCO approval for India launch Business Standard, October 01, 2025	Weight-loss drug Ozempic receives CDSCO approval for India launch	The race for a share of India's growing obesity market is set to intensify with the Central Drugs Standard Control Organisation (CDSCO) giving Danish drugmaker Novo Nordisk approval for its blockbuster diabetes drug Ozempic.
5 th October	AstraZeneca Pharma India gains CDSCO permission for Enhertu in HER2positive solid tumours Medical Dialogues, October 05, 2025	AstraZeneca Pharma India gains CDSCO permission for Enhertu in HER2positive solid tumours	AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication.
6 th October	Roche Pharma commits 1.5 billion Swiss franc investment in India over next five years Medical Dialogues, October 06, 2025	Roche Pharma commits 1.5 billion Swiss franc investment in India over next five years	New Delhi: Swiss healthcare giant Roche Pharma has announced a major investment plan of 1.5 billion Swiss Francs in India over the next five years. The company's commitment was revealed by Francois du Toit, Roche Pharma's Area Head for Central Eastern Europe, Turkey, Russia, and the Indian Subcontinent, during his speech at the Prosperity Summit.
7 th October	AstraZeneca Pharma India receives CDSCO approval for tumour agnostic use of Trastuzumab Deruxtecan Express Pharma, October 07, 2025	AstraZeneca Pharma India receives CDSCO approval for tumour agnostic use of Trastuzumab Deruxtecan	AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan (100mg/5mL vial lyophilised powder for concentrate for solution for infusion) for an additional indication in India.
8 th October	Eli Lilly's \$1 billion India investment to boost local CMOs and suppliers Business Today, October 08, 2025	Eli Lilly's \$1 billion India investment to boost local CMOs and suppliers	India's pharmaceutical industry was valued at about Rs 4.15 lakh crore in FY24 and is projected to reach Rs 10.8 lakh crore by 2030, according to the Department of Pharmaceuticals. The country accounts for nearly 20 per cent of global generic medicine exports by volume, as per the Indian Pharmaceutical Alliance.
8 th October	Fat-loss drug Mounjaro now India's No. 2 pharma brand	Fat-loss drug Mounjaro now India's No. 2 pharma brand	Sales of Mounjaro's rival, Wegovy, marketed by Novo Nordisk, have, however, plateaued around Rs 9 crore. The

	The Times of India, October 08, 2025		company is said to be cutting sales jobs, amid rising competition in the segment. Sales of Mounjaro's rival, Wegovy, marketed by Novo Nordisk, have, however, plateaued around Rs 9 crore. The company is said to be cutting sales jobs, amid rising competition in the segment.
8 th October	AstraZeneca gets regulator's nod to market cancer drug in India The Economic Times, October 08, 2025	AstraZeneca gets regulator's nod to market cancer drug in India	AstraZeneca Pharma has secured approval from India's drug regulator for its cancer treatment Trastuzumab Deruxtecan. This drug is now approved for adult patients with unresectable or metastatic HER2positive solid tumours. It is the first and only antibody drug conjugate in India with a tumour agnostic indication.
9 th October	Weight-loss drug Mounjaro is India's second-highest selling pharma brand Money Control, October 09, 2025	Weight-loss drug Mounjaro is India's second-highest selling pharma brand	Novo Nordisk Wegovy was launched in June. It's still listed in the top 40 brands. Analysts expect its performance to accelerate in the coming quarters as awareness and prescriptions rise. GST rate cut boost The GST reduction from 18 percent to 5 percent has significantly lowered the cost burden for chronic care patients.
9 th October	AstraZeneca gets nod to market cancer drug in India MID-DAY, October 09, 2025	AstraZeneca gets nod to market cancer drug in India	AstraZeneca Pharma on Tuesday said it has received approval from the national drug regulator to market a cancer treatment drug in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, market, and distribute Trastuzumab Deruxtecan for an additional indication in India, the drug firm said in a statement.
9 th October	Mounjaro becomes India's second-highest selling drug: What's driving its rise? India Today, October 09, 2025	Mounjaro becomes India's second-highest selling drug: What's driving its rise?	The drug, which contains the active ingredient tirzepatide, recorded sales of Rs 80 crore in September, overtaking the antacid brand Pan (at Rs 77 crore) and coming close behind GlaxoSmithKline's antibiotic Augmentin, which led with Rs 85 crore in sales.
10 th October	GSK calls for urgent focus on adult vaccination as ageing populations face rising disease burden Moneycontrol, October 10, 2025	GSK calls for urgent focus on adult vaccination as ageing populations face rising disease burden	As the world's population ages at an unprecedented pace, global biopharma major GSK is calling for a renewed focus on adult immunisation to prevent avoidable disease, reduce healthcare costs, and protect economic productivity.
13 th October	GSK's Nashik plant receives global BSI AMR Kitemark certification	GSK's Nashik plant receives global BSI AMR Kitemark certification	GSK's manufacturing facility in Nashik, Maharashtra, has become one of the first in India to achieve certification to the

	Express Pharma, October 13, 2025		international standard for antibiotic manufacturing, underscoring the company's commitment to tackling antimicrobial resistance (AMR) through responsible production and waste management.
14 th October	Bristol Myers Squibb launches heart med Mavacamten in India The Economic Times, October 14, 2025	Bristol Myers Squibb launches heart med Mavacamten in India	Building on its strategy of turning its \$13 billion buyout Mavacamten into a blockbuster brand, US pharma Bristol Myers Squibb (BMS) has announced the launch of the therapy in India under the brand name Kopozgo .Kopozgo (Mavacamten) is stated to be the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of a heart disease called obstructive hypertrophic cardiomyopathy (oHCM).
24 th October	Lilly and Cipla tie up to broaden access of weight-loss therapy The Times of India, October 24, 2025	Lilly and Cipla tie up to broaden access of weight-loss therapy	Eli Lilly and Cipla announced an agreement to distribute and promote tirzepatide in India under a second brand name, Yurpeak. This strategic agreement aims to expand the availability of tirzepatide by enabling broader access across the country beyond cities where Lilly already has an established presence.
28 th October	CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors Indian Pharma Post, October 28, 2025	CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors	Supported by key industry associations such as Pharmexcil, International Pharmaceutical Excipients Council (IPEC) India, Bulk Drug Manufacturers Association of India (BDMAI), and Organisation of Pharmaceutical Producers of India (OPPI), along with participation from regulatory authorities and policymakers, the 2025 edition reinforces its position as a credible platform for policy advocacy, industry collaboration, and sustainable business growth.
